MIRA
NASDAQMIRA Pharmaceuticals Inc.
Price$0.99-0.17 (-14.67%)
2026-03-092026-06-10
News · 26 weeks21+20%
2025-12-142026-06-07
Mix1590d
- SEC Filings8(53%)
- Market5(33%)
- Insider2(13%)
Latest news
25 items- INSIDERSEC Form 3 filed by new insider Mushak Andriy3 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)
- SECMIRA Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
- SECMIRA Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
- NEWSMIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1Agreement Establishes Global Exclusivity Across MIRA's Core Therapeutic Pipeline and Enhances Strategic Flexibility for Future Licensing and Partnership Opportunities MIAMI, FL / ACCESS Newswire / June 4, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company focused on the development of proprietary therapeutics for neurologic, neuropsychiatric, inflammatory, and metabolic disorders, today announced the execution of an Amended and Restated Exclusive License Agreement with MIRALOGX LLC, securing worldwide exclusive rights to MIRA-55 and SKNY-1.The amended agreement grants MIRA worldwide exclusive development, commercialization, subl
- SECMIRA Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
- NEWSMIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPNExpanded Global Intellectual Property Portfolio Enhances Strategic Flexibility and Long-Term Value Potential for Ketamir-2 MIAMI, FL / ACCESS Newswire / May 27, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company focused on the development of proprietary therapeutics for neurologic, neuropsychiatric, inflammatory, and metabolic disorders, today announced the execution of Amendment No. 1 to its exclusive Ketamir-2 license agreement with MIRALOGX LLC, expanding the Company's licensed territory from the United States, Canada, and Mexico to worldwide rights across all countries in which patent rights exist.The amended agreement incor
- SECSEC Form 10-Q filed by MIRA Pharmaceuticals Inc.10-Q - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
- NEWSMIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2Selective oral NMDA receptor modulator demonstrated favorable safety, tolerability, and pharmacokinetic profile supporting planned Phase 2a development in chemotherapy-induced peripheral neuropathy MIAMI, FL / ACCESS Newswire / May 14, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), today announced positive unblinded results from its completed Phase 1 clinical trial evaluating Ketamir-2, the Company's proprietary selective oral NMDA receptor modulator.The randomized, double-blind, placebo-controlled Phase 1 study evaluated the safety, tolerability, and pharmacokinetics of orally administered Ketamir-2 in healthy volunteers across single ascending dose (SAD) and mul
- SECMIRA Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
- NEWSMIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug CandidatePeer-reviewed publication highlights preclinical findings demonstrating weight loss, lipid normalization, and reduction of compulsive feeding and nicotine-seeking behaviors MIAMI, FL / ACCESS Newswire / May 13, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company focused on the development of investigational therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced the acceptance and publication of a peer-reviewed manuscript describing the preclinical pharmacology and activity of SKNY-1, the Company's oral investigational drug candidate being evaluated for obesity and nicotine addiction, in the Intern
- SECMIRA Pharmaceuticals Inc. filed SEC Form 8-K: Other Events8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
- INSIDERSEC Form 4 filed by Aminov Erez4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)
- SECSEC Form 10-K filed by MIRA Pharmaceuticals Inc.10-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
- SECMIRA Pharmaceuticals Inc. filed SEC Form 8-K: Other Events8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
- NEWSMIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical StudiesPreviously shown to deliver morphine-comparable pain relief without opioid-related risks in a validated inflammatory pain model, supporting planned IND submission for inflammatory painMIAMI, FL / ACCESS Newswire / March 23, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapies for neurologic, neuropsychiatric, and metabolic disorders, today announced new preclinical data demonstrating that Mira-55 did not produce cannabinoid-like central nervous system (CNS) side effects across a comprehensive battery of validated behavioral assays. The observed profile was differentiated from both Δ9-tetrahydrocannabinol
- NEWSMIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2Advancing a selective oral NMDA receptor modulator toward Phase 2a in chemotherapy-induced peripheral neuropathy following favorable Phase 1 safety and tolerability findingsMIAMI, FLORIDA / ACCESS Newswire / March 4, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral therapeutics for neuropathic and inflammation-driven pain conditions, metabolic disorders, and oncology-related indications, today announced completion of dosing in its Phase 1 clinical trial evaluating Ketamir-2, the Company's proprietary selective oral NMDA receptor modulator.The randomized, double-blind, placebo-controlled study enrolled 56
- SECMIRA Pharmaceuticals Inc. filed SEC Form 8-K: Other Events8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
- INSIDERAminov Erez was granted 125,000 shares, exercised 613,595 shares at a strike of $0.96 and sold $1,294,685 worth of shares (613,595 units at $2.11), increasing direct ownership by 4% to 3,592,666 units (SEC Form 5)5 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)
- NEWSMIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a StudyCompany to Participate in BIO Partnering Summit and Present Phase 1 Ketamir-2 Data at American Association for Cancer Research (AACR)Annual MeetingMIAMI, FLORIDA / ACCESS Newswire / February 3, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral therapeutics for neuropathic and inflammation-driven pain conditions, metabolic disorders, and oncology-related indications, today announced that it has initiated dosing in the final cohort of its Phase 1 multiple ascending dose (MAD) clinical trial evaluating Ketamir-2, its lead oral NMDA receptor antagonist.To date, 50 healthy volunteers have already been dosed, wh
- SECMIRA Pharmaceuticals Inc. filed SEC Form 8-K: Other Events8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
- SECMIRA Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
- SECMIRA Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
- SECSEC Form 424B5 filed by MIRA Pharmaceuticals Inc.424B5 - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
- SECSEC Form 10-Q filed by MIRA Pharmaceuticals Inc.10-Q - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
- NEWSMIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a IndicationAdvancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track consideration MIAMI, FLORIDA / ACCESS Newswire / October 24, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced the initiation of the multiple ascending dose (MAD) portion of its ongoing Phase 1 clinical trial evaluating its lead oral candidate, Ketamir-2, in healthy volunteers. The Company also announced that it has selected chemotherapy-induced peripheral neuropathy (CIPN)
MIRA FAQ
5 questionsWhere does MIRA stock trade?
MIRA Pharmaceuticals Inc. (MIRA) is listed on NASDAQ.What sector and industry is MIRA in?
MIRA Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did MIRA Pharmaceuticals Inc. go public?
MIRA Pharmaceuticals Inc. (MIRA) completed its IPO in 2023.What companies are similar to MIRA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare MIRA side-by-side with any of them on Quantisnow.How can I track MIRA on Quantisnow?
Quantisnow aggregates MIRA Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MIRA to receive live email and push alerts on every new disclosure.